Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Accured Expenses (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Change in Accured Expenses for 11 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 128.36% to $9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.3 million, a 49.23% increase, with the full-year FY2025 number at -$5.3 million, up 49.23% from a year prior.
  • Change in Accured Expenses was $9.0 million for Q4 2025 at Intellia Therapeutics, up from -$715000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $18.4 million in Q4 2021 to a low of -$22.4 million in Q1 2024.
  • A 5-year average of $1.2 million and a median of $3.0 million in 2022 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 552.33% in 2021; the steepest drop was 2692.09% in 2021.
  • Intellia Therapeutics' Change in Accured Expenses stood at $18.4 million in 2021, then tumbled by 83.33% to $3.1 million in 2022, then soared by 194.01% to $9.0 million in 2023, then plummeted by 56.23% to $4.0 million in 2024, then soared by 128.36% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Change in Accured Expenses are $9.0 million (Q4 2025), -$715000.0 (Q3 2025), and $832000.0 (Q2 2025).